Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.64 |
| ▸ | RET | P07949 | 3/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 3/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29356365 | 1.00 | HDAC1 (0.64) | HDAC1RETGPR119HSD11B1JAK1 | |
| SCHEMBL20468896 | 0.87 | HDAC1 (0.60) | HDAC1RETGPR119HSD11B1JAK1 | |
| SCHEMBL5041626 | 0.86 | HDAC1 (0.59) | HDAC1RETGPR119HSD11B1JAK1 | |
| SCHEMBL22909889 | 0.86 | HDAC1 (0.59) | HDAC1RETGPR119HSD11B1JAK1 | |
| SCHEMBL21262007 | 0.86 | HDAC1 (0.59) | HDAC1RETGPR119HSD11B1JAK1 | |
| SCHEMBL24428346 | 0.86 | HDAC1 (0.59) | HDAC1RETGPR119HSD11B1JAK1 | |
| SCHEMBL20456823 | 0.86 | HDAC1 (0.62) | HDAC1RETGPR119HSD11B1JAK1 | |
| SCHEMBL29600378 | 0.86 | HDAC1 (0.59) | HDAC1RETGPR119HSD11B1JAK1 | |
| SCHEMBL20071342 | 0.84 | HDAC1 (0.57) | HDAC1RETGPR119HSD11B1JAK1 | |
| SCHEMBL25310645 | 0.84 | HDAC1 (0.57) | HDAC1RETGPR119HSD11B1JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954216-B2 | BMP-signal-inhibiting compound | RIKEN (JP) | 2021-03-23 | — | — | US | disclosed |
| US-20190337926-A1 | BMP-SIGNAL-INHIBITING COMPOUND | RIKEN (JP) | 2019-11-07 | — | — | US | disclosed |
| WO-2018124001-A1 | BMP-SIGNAL-INHIBITING COMPOUND | 国立研究開発法人理化学研究所 | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954216-B2 | BMP-signal-inhibiting compound | BMP1, BMP2, BMP4 | HDAC1 718/4885RET 1123/4885GPR119 1381/4885 |
| US-20190337926-A1 | BMP-SIGNAL-INHIBITING COMPOUND | BMP1, BMP2, BMPR2 | HDAC1 858/4885RET 1917/4885GPR119 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.